Pharmaceutical Technology, May 2, 2010 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pharmaceutical Technology, May 2, 2010
Online Exclusives
Validation by Numbers
By Russell E. Madsen Jr.
A book helps statistics novices prepare to comply with the US Food and Drug Administration's draft guidance on process validation.
Special Report
Thinking Inside the Box
By Erik Greb
A modular approach to biopharmaceutical production could bring process flexibility, and contract manufacturing organizations are beginning to take notice.
Ingredients Insider
Exploring Catalysis in API Synthesis
By Patricia Van Arnum
Chemocatalysis and biocatalysis are important elements of an effective strategy for improving yield and stereoselectivty.
Peer-Reviewed Research
Skin Permeation of Rosiglitazone from Transdermal Matrix Patches
By N. Damodharan , Gopa Roy , Soma Ghosh , Biswajit Mukherjee, PhD
The authors demonstrate that sustained-release delivery can help avoid the risk of sudden higher-blood concentration of a drug to avoid toxicity.
Experimental Considerations in Headspace Gas Chromatography
By Laila Kott , Hong Ming Chen
In this case study of amines, the authors discuss several parameters to be considered in developing a headspace GC method.
From The Editor
A Very Brady FDA
By Michelle Hoffman
FDA wants industry to talk to them about the science underlying process innovations—really.
PharmTech Talk
Inactive Excipients and Other Myths
By Angie Drakulich
Agreement on standards for excipient qualification, development, and fair pricing is underway.
Agent-in Place
Mixed Blessings
By Control, a senior compliance officer
When vessels, seals, and cooling units go haywire, operators must get in the mix.
News
Report from Brazil
By Hellen Berger
The growth of Brazil's generic-drug market is on a fast track, but what are the projections for the sector's future?
In the Spotlight
In the Spotlight
Editors' Picks of pharmaceutical science and technology innovations
Washington Report
Health Reform to Transform Coverage, Costs
By Jill Wechsler
Manufacturers will pay new fees but anticipate expanded drug use and safeguards for innovation.
Statistical Solutions
Statistical Solutions: Bergum's Method Recognized
By Lynn D. Torbeck
A method for determining sample size is finally getting some respect.
Insider Solutions
Inside USP: The USP Convention
By Susan J. Schniepp
Defining the Next Five Years.
Outsourcing Outlook
The Lilly Way
By Jim Miller
Eli Lilly faces up to the new realities of the bio/pharmaceutical industry through outsourcing.
Industry Leaders: Q&A
Q&A with Schenk AccuRate's Chad Lorensen
Lorensen discusses client demands and industry trends.
Viewpoint
Enterprise-Level Change Control
By Marina Aslanyan
A Pharma Business Imperative.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
Click here